Antiamyloid Monoclonal Antibodies in Alzheimer’s Disease, Part 1: Patient Selection

What is it about?

New therapies targeting amyloid beta protein in Alzheimer's disease have dramatically changed the landscape of dementia care in the U.S. Careful biomarker-informed diagnosis is now much more common, driven in part by the need to assess for eligibility for these new therapies. In this manuscript, we provide commentary on the complex and challenging patient selection issues that arises in clinical practice.

Featured Image